Orthopoxvirus-specific antibodies wane to undetectable levels one year after MVA-BN vaccination of at-risk individuals

Leanne P.M. van Leeuwen,Marc C. Shamier,Babs E. Verstrepen,Hannelore M. Götz,Katharina S. Schmitz,Najlae Akhiyate,Koen Wijnans,Susanne Bogers,Martin E. van Royen,Eric C.M. van Gorp,Marion P.G. Koopmans,Rory D. de Vries,Corine H. GeurtsvanKessel,Luca M. Zaeck

DOI: https://doi.org/10.1101/2024.08.13.24311601

2024-08-14

Abstract:In response to the 2022-2023 mpox outbreak, widespread vaccination with modified vaccinia Ankara-Bavarian Nordic was initiated. Here, we demonstrate that orthopoxvirus-specific binding and MVA-neutralizing antibodies wane to undetectable levels one year post-vaccination in at-risk individuals without pre-existing immunity. Continuous surveillance is essential to understand the impact of declining antibody levels.